|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0043240,
umls-concept:C0072980,
umls-concept:C0144576,
umls-concept:C0166417,
umls-concept:C0205195,
umls-concept:C0243192,
umls-concept:C0443199,
umls-concept:C0522776,
umls-concept:C0597357,
umls-concept:C0752063,
umls-concept:C0812230,
umls-concept:C1514873,
umls-concept:C1552644,
umls-concept:C1823153,
umls-concept:C1879547,
umls-concept:C2349976,
umls-concept:C2825200
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2009-11-6
|
|
pubmed:abstractText |
Sirolimus-eluting coronary stents (SESs) and paclitaxel-eluting coronary stents (PESs) are used to reduce restenosis but have different sites of action. The molecular targets of sirolimus overlap with those of the peroxisome proliferator-activated receptor (PPAR)gamma agonist rosiglitazone (RSG) but the consequence of this interaction on endothelialization is unknown.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Heme Oxygenase-1,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/MTOR protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/PPAR gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-akt,
http://linkedlifedata.com/resource/pubmed/chemical/Sirolimus,
http://linkedlifedata.com/resource/pubmed/chemical/TOR Serine-Threonine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazolidinediones,
http://linkedlifedata.com/resource/pubmed/chemical/Tubulin Modulators,
http://linkedlifedata.com/resource/pubmed/chemical/rosiglitazone
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1524-4571
|
|
pubmed:author |
pubmed-author:AcampadoEduardoE,
pubmed-author:ChengQiQ,
pubmed-author:DavisTalinaT,
pubmed-author:EppihimerMichaelM,
pubmed-author:EzellTuckerT,
pubmed-author:FinnAloke VAV,
pubmed-author:GoldHerman KalmanHK,
pubmed-author:JohnMichaelM,
pubmed-author:KarmaliVinitV,
pubmed-author:KolodgieFrank DFD,
pubmed-author:LajoieScottS,
pubmed-author:LiZ CZC,
pubmed-author:NakazawaGakuG,
pubmed-author:PolavarapuRohiniR,
pubmed-author:RaghunathanChitraC,
pubmed-author:VirmaniRenuR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
6
|
|
pubmed:volume |
105
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1003-12
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19797172-Animals,
pubmed-meshheading:19797172-Aorta,
pubmed-meshheading:19797172-Cells, Cultured,
pubmed-meshheading:19797172-Drug-Eluting Stents,
pubmed-meshheading:19797172-Endothelial Cells,
pubmed-meshheading:19797172-Graft Occlusion, Vascular,
pubmed-meshheading:19797172-Heme Oxygenase-1,
pubmed-meshheading:19797172-Humans,
pubmed-meshheading:19797172-Hypoglycemic Agents,
pubmed-meshheading:19797172-Immunosuppressive Agents,
pubmed-meshheading:19797172-Models, Biological,
pubmed-meshheading:19797172-PPAR gamma,
pubmed-meshheading:19797172-Paclitaxel,
pubmed-meshheading:19797172-Protein Kinases,
pubmed-meshheading:19797172-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:19797172-Rabbits,
pubmed-meshheading:19797172-Sirolimus,
pubmed-meshheading:19797172-TOR Serine-Threonine Kinases,
pubmed-meshheading:19797172-Thiazolidinediones,
pubmed-meshheading:19797172-Tubulin Modulators
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activation.
|
|
pubmed:affiliation |
Department of Medicine/Heart and Vascular Center, Emory University School of Medicine, Atlanta, GA, USA. avfinn@emory.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
